Venture Capital Daily | "Gaozhong Technology" received 300 million yuan in Series C financing; "Jifan Bio" completed nearly 150 million yuan in Series A financing; and early projects worthy of attention today

Venture Capital Daily | “Gaozhong Technology” received 300 million yuan in Series C financing; “Jifan Bio” completed nearly 150 million yuan in Series A financing; and early projects worthy of attention today

#Venture #Capital #Daily #Gaozhong #Technology #received #million #yuan #Series #financing #Jifan #Bio #completed #million #yuan #Series #financing #early #projects #worthy #attention #today

Please check the Venture Capital Daily Report on February 10. The Venture Capital Daily contains the financing news reported by the “36Kr Venture Capital Channel” today, as well as the early start-up projects in various fields that we are paying attention to, enjoy!


Financing disclosure:

  • 36氪 Exclusive | “Gaozhong Technology” received 300 million RMB in Series C financing to provide “industry + AI” solutions for finance, civil aviation, smart cities, etc.

36氪 was exclusively informed that Shanghai Gaozhong Information Technology Co., Ltd. (hereinafter referred to as “Gaozhong Technology”) has completed a 300 million yuan C round of financing, which was jointly led by Qingdao State-owned Assets Platform Qingdao Guoxin Financial Holdings, Qingdao City Investment, and Qingdao Jiaozhou Industrial Fund , DaEu Capital acted as financial advisor.

In the first half of 2020, Gaozhong Technology completed a series B financing of nearly 100 million yuan led by Tianqi Venture Capital. Prior to this, the company had received investment from Haiying Industry Fund, Tianan Financial Holdings, Yida Capital, Nanjing New Kinetic Energy Investment and other institutions.

Gaozhong Technology was established in 2014. Based on artificial intelligence and big data, it provides “industry + AI” solutions for finance, transportation (civil aviation) and smart city scenarios. Its current head customers include China Merchants Bank, Industrial and Commercial Bank of China, Pudong Airport, Baiyun Airport, China Telecom, China Railway Corporation, Shimao Real Estate, Forbidden City, etc… (click here for details)

Project report:

  • Revenue exceeded 200 million yuan, “72 Media” entered the advertising market with tissue machine launches

Focusing on offline traffic acquisition, a new type of large-screen advertisements began to appear in public toilets and lounges in office buildings, shopping malls, stations, subways and other places. Related companies use automatic tissue machines with electronic large screens to directly place advertisements, and use related technologies such as the Internet of Things, big data analysis, video networking, and light and shadow interaction to connect online and offline for precise marketing.

A few days ago, the “72 Media” that 36Kr came into contact with is one of the practitioners of this model, and has already had stable scene cooperation and a large number of users. The company was founded in 2018. Up to now, its revenue has exceeded 200 million yuan, the number of users has exceeded 1 million, the number of daily active users has exceeded 20,000, and the number of daily users has exceeded 2,000, and the total number of orders has exceeded 640,000… . (Click here for details)

  • “Semester Financial Services” received millions of angel financing, positioning the education industry as a financial digital platform

36氪 learned that “Semester Financial Services” recently announced the completion of millions of angel financing, led by the technology financial company “Lingyue Technology”. This round of financing will be used for corporate traffic activation, data procurement, system research and development, and talent replenishment.

Semester Financial Services was established in January 2019. It is a technology company focusing on financial products and solutions in the education industry. It is committed to using big data, AI, cloud computing and other technologies to improve the efficiency of the education industry and serve upstream and downstream organizations in the education industry. .

The semester financial service is positioned as a financial digital platform for the education industry. In 2019, Semester Financial Services has reached in-depth strategic cooperation with “Chanming Technology”, a digital education service provider with more than 70,000 contracted educational institutions, and has launched three products: credit term, school easy loan, and learning credit… .. (Click here for details)

Industry News:

  • “Ronglian Cloud Communications” today IPO, can the story of the Chinese version of Twilio be reproduced?

At 10:30 pm on February 9th, Beijing time, the intelligent communication cloud service provider “Ronglian Cloud Communications” (hereinafter referred to as “Ronglian”) officially landed on the NYSE with the stock code “RAAS”. In this IPO, Ronglian Cloud Communications issued a total of 20 million ADS shares at an issue price of US$16, which is higher than the guidance range. After the Green Shoes, Rong Lian raised a total of 368 million US dollars.

Before the IPO, Ronglian Cloud Communications has won the favor of many first-line investment institutions. The largest institutional shareholder Main Access Limited holds 21.56% of the shares, Sequoia Capital holds 20.75%, in addition to Trust Capital and Prospect Avenue Capital (PAC), Holds 14.91% and 4.94% of the shares respectively, CEO Sun Changxun holds 15.21% of the shares…… (click here for details)

Medical treatment

Financing disclosure:

  • Promoting the research and development of sample pre-processing products, “Jifan Bio” completed nearly 150 million yuan in Series A financing

It is reported that “Jifan Bio” has recently completed a round of financing of nearly 150 million yuan. This round of financing was jointly led by Legend Capital and Sequoia Capital China Fund. The funds raised will be mainly used to promote the company’s sample pre-processing product research and development, related channel construction and overseas market expansion.

“Jifan Bio” was established in 2016 to provide stable, reliable, cost-effective biological reagents and professional technical services for precision medicine and molecular diagnostic users. The company has four core technology platforms: medical sample preservation technology platform, column membrane nucleic acid extraction reagent platform, magnetic bead material and high-throughput instrument integration platform, Direct qPCR/qRT-PCR detection technology platform, and more than 300 rich products , To provide customers with integrated, personalized and customized sample pre-processing solutions from biological sample preservation, extraction to detection. The company currently has a number of invention patents, more than ten utility model patents, six software copyrights…… (click here for details)

  • Focusing on the research and development of pen injectors, “Han Erxi” completed 10 million yuan Pre-A round of financing

It is reported that “Han Ersi” has recently completed 10 million yuan of Pre-A round of financing. This round of financing was led by Qianhui Capital, and the funds raised will be used to complete the introduction of automated production equipment and implement mass automated production of injection pens. Prior to this, the company had also received investment from CCB Medical Growth Fund and Kun High-tech Venture Capital.

“Han Ersi” was established in November 2014. It is a pen-type syringe developer focusing on new drug delivery methods. The injection pen is a special high-precision syringe used for cartridge medicine. It is characterized by precise quantitative injection, independent medical treatment, and safe and convenient use. The scope of application includes: autonomous treatment of chronic diseases such as insulin and growth hormone; precision medication such as interferon, various cells, genes, and biological agents; and high-end beauty needles used in consumer medical scenarios… (detailed content This learned)

  • Entering the in vitro diagnostic industry from molecular diagnostics, “Econo” completed nearly 100 million yuan in A2 round of financing

It is reported that “Econo” has recently completed an A2 round of financing of nearly 100 million yuan. This round of financing is invested by Innovation Workshop, and the funds raised will be mainly used for clinical trials of instrument and reagent products, application for NMPA registration certificate and product conversion. Prior to this, the company had also received investment from Chende Capital, Zhen Fund, and Nanchuang Capital.

“Econo” was established in July 2018. It is a Sino-foreign joint venture focusing on the in vitro diagnostic (IVD) industry. It is engaged in the automation of molecular diagnostic laboratories and develops and promotes a fully automated nucleic acid detection platform suitable for testing laboratories. And a series of test kits for clinical diagnosis of severe infectious diseases. Headquartered in Xiuzhou District, Jiaxing City, Zhejiang Province, it has established R&D centers in San Diego and Shanghai, and has complete molecular biology equipment and laboratories… (click here for details)

  • 36Kr First Release丨Promoting clinical trials for the treatment of hepatitis B, “Drug Ranch” completed US$56 million financing

36 Krypton learned that “Drug Ranch” today announced the completion of US$56 million in financing. As of the B round, investors include BioVida (BVCF), WuXi AppTec Enterprise Venture Fund, Zhongnan Venture Capital, Detong Capital and Zhejiang Minsheng Investment. The funds raised will be used to conduct clinical trials of the DF-006 drug. The drug is the first-in-class oral drug developed by the company to treat hepatitis B virus (HBV) and other liver diseases. The financing will further advance the research and development of other cancer and autoimmune disease product pipelines in the “Drug Ranch”.

Founded in 2015, “Medicine Ranch” is a biotechnology company rooted in China and the United States, using genetics and artificial intelligence technologies to develop innovative therapies for hepatitis B, tumors and autoimmune diseases. The company’s IDInVivo platform combines genetics and artificial intelligence to directly discover new drug targets in living animals with normal immune functions and use breakthrough technologies to create new treatment methods. Using the IDInVivo platform, “Drug Ranch” has discovered multiple new targets for innate immunity, and is currently rapidly advancing multiple First-in-class drugs into the clinical stage… (click here for details)


Financing disclosure:

  • 36氪 Exclusive | “Art Treasure Education” completed over 40 million US dollars D+ round of financing, the total amount of D round financing exceeded 250 million US dollars

36氪 learned that the online quality education brand “Art Treasure Education” completed a D+ round of financing of more than 40 million US dollars, which was jointly invested by funds under CICC Capital, Five Star Holdings Singnach Capital, Hongtai Fund, and Guohai Innovation Capital. Taihe Capital continued to act as the exclusive financial advisor. So far, the total financing amount of the Series D series of Artbao Education has exceeded 250 million US dollars.

Artbao Education was founded in 2014 and provides online aesthetic education courses for users and families aged 3-18. At present, the business covers more than 160 countries and regions around the world, with a total of 260 million teaching services provided. The core teaching product business has accumulated more than 5 million registered users and accumulated more than 500,000 paying students.

In the process of development, Fine Art Education has successively received investments from TPG, Tencent, Lanchi Ventures, and Shunwei Capital. Up to now, the accumulated financing amount of Artbao Education has exceeded 2.25 billion yuan… (click here for details)


  • Forefront丨It plans to acquire 51.8% equity of Kerry Logistics for RMB 17.5 billion, and SF Holdings opens daily limit

SF Express has launched an international freight forwarding business.

36 Krypton learned that SF Holdings officially issued an announcement on the evening of February 9th that the company intends to privately issue shares to no more than 35 specific targets, raising no more than 22 billion yuan for five projects and supplements including the automatic upgrade of express equipment Working capital. In addition, the company intends to acquire a 51.8% stake in Kerry Logistics through a partial offer in cash.

SF Express stated that the acquisition aims to further enhance the ability of integrated integrated logistics solutions and improve the strategic layout of freight forwarding and international business. If the transaction is successfully completed, Kerry Logistics will still maintain its listing on the Main Board of the Stock Exchange, and its public shareholding ratio will be changed from 25% to 15%.

The Securities Times quoted industry insiders as saying, “The’marriage’ of SF Holdings Kerry Logistics has not only made up for the shortcomings of international freight, but also pointed to the’cake’ of duty-free logistics in outlying islands”… (details Click here to learn)

36Kr’s public account


Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *